The treatment of delirium or psychosis in patients with Parkinson’s disease (PD) can be complicated by the limited number of pharmacological agents that can be used in this population. Typical and atypical antipsychotics are contraindicated, as they can worsen motor symptoms. The treatment of acute delirium is even more complicated in the hospital setting, as many medications deemed safer in this population are only available in oral form. We present a case of acute delirium in a patient with PD, likely precipitated by a polypharmacy interaction of new medications, that was successfully managed by transferring the patient to the intensive care unit and administering dexmedetomidine for 72 hours.
Citations
Citations to this article as recorded by
Drug-induced psychotic syndrome Jana Hroudová Klinická farmakologie a farmacie.2024; 38(2): 83. CrossRef
Toxin Induced Parkinsonism and Hospitalization Related Adverse Outcome Mitigation for Parkinson’s Disease: A Comprehensive Review Kenneth R. Dalton, Charles J. Kidd, Nawaz Hack Journal of Clinical Medicine.2023; 12(3): 1074. CrossRef
Fountain of youth—Targeting autophagy in aging Lea Danics, Anna Anoir Abbas, Balázs Kis, Karolina Pircs Frontiers in Aging Neuroscience.2023;[Epub] CrossRef
Effect of dexmedetomidine on postoperative delirium in patients undergoing brain tumour resections: study protocol of a randomised controlled trial Dexiang Wang, Ruowen Li, Shu Li, Juan Wang, Min Zeng, Jia Dong, Xiaoyuan Liu, Nan Lin, Yuming Peng BMJ Open.2021; 11(11): e051584. CrossRef